Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1997;76(1):93–99. doi: 10.1038/bjc.1997.342

Epirubicin combined with estramustine phosphate in hormone-resistant prostate cancer: a phase II study.

E H Hernes 1, S D Fosså 1, S Vaage 1, P Ogreid 1, A Heilo 1, E Paus 1
PMCID: PMC2223802  PMID: 9218739

Abstract

Twenty-four assessable patients with hormone-resistant prostate cancer (HRPC) were to receive daily doses of oral estramustine phosphate (EMP), 10 mg kg(-1), and intravenous epirubicin (EPR) infusions, 100 mg m(-2), every third week up to a cumulative dose of 500 mg m(-2). Biochemical response [> or = 50% reduction in pretreatment serum prostate-specific antigen (PSA) after three cycles of > or = 3 weeks' duration] was demonstrated in 13 of 24 patients included (54%). No objective response (WHO criteria) was observed, although seven of nine evaluable patients achieved a > or = 50% serum PSA reduction. Subjective improvement (pain score, performance status) occurred in 7 of 24 patients, whereas nine patients progressed subjectively. There was no correlation between subjective and biochemical response. Biochemical progression (> or = 50% increase of nadir PSA) occurred after a median of 12 weeks. All but two patients were alive after a median follow-up time of 8.7 months for surviving patients (range 3.3-13.2). Eight patients experienced grade 3/4 leucopenia, with no indication of cumulative myelosuppression. Cardiovascular toxicity was experienced by four patients. Two patients developed angioedema twice, in one patient requiring hospitalization at the intensive ward. Based on this limited series, the combination of EPR and EMP in patients with HRPC is tolerable and appears to be effective in terms of significant PSA reduction. The results warrant further investigations of the two drugs and, in particular, of the clinical significance of > or = 50% PSA decrease in patients with HRPC.

Full text

PDF
93

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benson R. C., Jr, Gill G. M. Estramustine phosphate compared with diethylstilbestrol. A randomized, double-blind, crossover trial for stage D prostate cancer. Am J Clin Oncol. 1986 Aug;9(4):341–351. doi: 10.1097/00000421-198608000-00014. [DOI] [PubMed] [Google Scholar]
  2. Brausi M., Jones W. G., Fosså S. D., de Mulder P. H., Droz J. P., Lentz M. A., van Glabbeke M., Pawinski A. High dose epirubicin is effective in measurable metastatic prostate cancer: a phase II study of the EORTC Genitourinary Group. Eur J Cancer. 1995 Sep;31A(10):1622–1626. doi: 10.1016/0959-8049(95)00193-m. [DOI] [PubMed] [Google Scholar]
  3. Csapo Z., Brand K., Walther R., Fokas K. Comparative experimental study of the serum prostate specific antigen and prostatic acid phosphatase in serially transplantable human prostatic carcinoma lines in nude mice. J Urol. 1988 Nov;140(5):1032–1038. doi: 10.1016/s0022-5347(17)41921-5. [DOI] [PubMed] [Google Scholar]
  4. Eisenberger M. A., Simon R., O'Dwyer P. J., Wittes R. E., Friedman M. A. A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol. 1985 Jun;3(6):827–841. doi: 10.1200/JCO.1985.3.6.827. [DOI] [PubMed] [Google Scholar]
  5. Elomaa I., Kellokumpu-Lehtinen P., Rannikko S., Alfthan O. Hormone-resistant metastatic prostate cancer. Comparisons between estramustine phosphate and low-dose epirubicin treatments. Eur Urol. 1991;19(1):12–15. [PubMed] [Google Scholar]
  6. Fosså S. D., Aaronson N. K., Newling D., van Cangh P. J., Denis L., Kurth K. H., de Pauw M. Quality of life and treatment of hormone resistant metastatic prostatic cancer. The EORTC Genito-Urinary Group. Eur J Cancer. 1990;26(11-12):1133–1136. doi: 10.1016/0277-5379(90)90269-y. [DOI] [PubMed] [Google Scholar]
  7. Fosså S. D., Paus E., Lindegaard M., Newling D. W. Prostate-specific antigen and other prognostic factors in patients with hormone-resistant prostatic cancer undergoing experimental treatment. Br J Urol. 1992 Feb;69(2):175–179. doi: 10.1111/j.1464-410x.1992.tb15491.x. [DOI] [PubMed] [Google Scholar]
  8. Fosså S. D., Paus E. Reduction of serum prostate-specific antigen during endocrine or cytotoxic treatment of hormone-resistant cancer of the prostate. A preliminary report. Eur Urol. 1994;26(1):29–34. doi: 10.1159/000475338. [DOI] [PubMed] [Google Scholar]
  9. Fosså S. D., Waehre H., Paus E. The prognostic significance of prostate specific antigen in metastatic hormone-resistant prostate cancer. Br J Cancer. 1992 Jul;66(1):181–184. doi: 10.1038/bjc.1992.239. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Francini G., Petrioli R., Manganelli A., Cintorino M., Marsili S., Aquino A., Mondillo S. Weekly chemotherapy in advanced prostatic cancer. Br J Cancer. 1993 Jun;67(6):1430–1436. doi: 10.1038/bjc.1993.265. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Ganzina F. 4'-epi-doxorubicin, a new analogue of doxorubicin: a preliminary overview of preclinical and clinical data. Cancer Treat Rev. 1983 Mar;10(1):1–22. doi: 10.1016/s0305-7372(83)80029-2. [DOI] [PubMed] [Google Scholar]
  12. Gleave M. E., Hsieh J. T., Wu H. C., von Eschenbach A. C., Chung L. W. Serum prostate specific antigen levels in mice bearing human prostate LNCaP tumors are determined by tumor volume and endocrine and growth factors. Cancer Res. 1992 Mar 15;52(6):1598–1605. [PubMed] [Google Scholar]
  13. Gunnarsson P. O., Davidsson T., Andersson S. B., Backman C., Johansson S. A. Impairment of estramustine phosphate absorption by concurrent intake of milk and food. Eur J Clin Pharmacol. 1990;38(2):189–193. doi: 10.1007/BF00265983. [DOI] [PubMed] [Google Scholar]
  14. Hedner T., Samuelsson O., Lunde H., Lindholm L., Andrén L., Wiholm B. E. Angio-oedema in relation to treatment with angiotensin converting enzyme inhibitors. BMJ. 1992 Apr 11;304(6832):941–946. doi: 10.1136/bmj.304.6832.941. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Horio Y., Takahashi T., Kuroishi T., Hibi K., Suyama M., Niimi T., Shimokata K., Yamakawa K., Nakamura Y., Ueda R. Prognostic significance of p53 mutations and 3p deletions in primary resected non-small cell lung cancer. Cancer Res. 1993 Jan 1;53(1):1–4. [PubMed] [Google Scholar]
  16. Hudes G. R., Greenberg R., Krigel R. L., Fox S., Scher R., Litwin S., Watts P., Speicher L., Tew K., Comis R. Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. J Clin Oncol. 1992 Nov;10(11):1754–1761. doi: 10.1200/JCO.1992.10.11.1754. [DOI] [PubMed] [Google Scholar]
  17. Jones W. G., Fosså S. D., Bono A. V., Klijn J. G., De Pauw M., Sylvester R. European Organization for Research and Treatment of Cancer (EORTC) phase II study of low-dose weekly epirubicin in metastatic prostate cancer. Cancer Treat Rep. 1987 Dec;71(12):1317–1318. [PubMed] [Google Scholar]
  18. Kelly W. K., Scher H. I., Mazumdar M., Vlamis V., Schwartz M., Fossa S. D. Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol. 1993 Apr;11(4):607–615. doi: 10.1200/JCO.1993.11.4.607. [DOI] [PubMed] [Google Scholar]
  19. La Rocca R. V., Danesi R., Cooper M. R., Jamis-Dow C. A., Ewing M. W., Linehan W. M., Myers C. E. Effect of suramin on human prostate cancer cells in vitro. J Urol. 1991 Feb;145(2):393–398. doi: 10.1016/s0022-5347(17)38351-9. [DOI] [PubMed] [Google Scholar]
  20. Martoni A., Melotti B., Guaraldi M., Pacciarini M. A., Riva A., Pannuti F. High-dose epirubicin for untreated patients with advanced tumours: a phase I study. Eur J Cancer. 1990;26(11-12):1137–1140. doi: 10.1016/0277-5379(90)90270-4. [DOI] [PubMed] [Google Scholar]
  21. Miller A. B., Hoogstraten B., Staquet M., Winkler A. Reporting results of cancer treatment. Cancer. 1981 Jan 1;47(1):207–214. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  22. Newling D. W., Fossa S. D., Tunn U. W., Kurth K. H., de Pauw M., Sylvester R. Mitomycin C versus estramustine in the treatment of hormone resistant metastatic prostate cancer: the final analysis of the European Organization for Research and Treatment of Cancer, genitourinary group prospective randomized phase III study (30865). J Urol. 1993 Dec;150(6):1840–1844. doi: 10.1016/s0022-5347(17)35911-6. [DOI] [PubMed] [Google Scholar]
  23. Pavone-Macaluso M., de Voogt H. J., Viggiano G., Barasolo E., Lardennois B., de Pauw M., Sylvester R. Comparison of diethylstilbestrol, cyproterone acetate and medroxyprogesterone acetate in the treatment of advanced prostatic cancer: final analysis of a randomized phase III trial of the European Organization for Research on Treatment of Cancer Urological Group. J Urol. 1986 Sep;136(3):624–631. doi: 10.1016/s0022-5347(17)44996-2. [DOI] [PubMed] [Google Scholar]
  24. Pienta K. J., Redman B., Hussain M., Cummings G., Esper P. S., Appel C., Flaherty L. E. Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol. 1994 Oct;12(10):2005–2012. doi: 10.1200/JCO.1994.12.10.2005. [DOI] [PubMed] [Google Scholar]
  25. Seidman A. D., Scher H. I., Petrylak D., Dershaw D. D., Curley T. Estramustine and vinblastine: use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol. 1992 Mar;147(3 Pt 2):931–934. doi: 10.1016/s0022-5347(17)37426-8. [DOI] [PubMed] [Google Scholar]
  26. Smith P. H., Bono A., Calais da Silva F., Debruyne F., Denis L., Robinson P., Sylvester R., Armitage T. G. Some limitations of the radioisotope bone scan in patients with metastatic prostatic cancer. A subanalysis of EORTC trial 30853. The EORTC Urological Group. Cancer. 1990 Sep 1;66(5 Suppl):1009–1016. doi: 10.1002/cncr.1990.66.s5.1009. [DOI] [PubMed] [Google Scholar]
  27. Smith P. H., Suciu S., Robinson M. R., Richards B., Bastable J. R., Glashan R. W., Bouffioux C., Lardennois B., Williams R. E., de Pauw M. A comparison of the effect of diethylstilbestrol with low dose estramustine phosphate in the treatment of advanced prostatic cancer: final analysis of a phase III trial of the European Organization for Research on Treatment of Cancer. J Urol. 1986 Sep;136(3):619–623. doi: 10.1016/s0022-5347(17)44995-0. [DOI] [PubMed] [Google Scholar]
  28. Soloway M. S., Hardeman S. W., Hickey D., Raymond J., Todd B., Soloway S., Moinuddin M. Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer. 1988 Jan 1;61(1):195–202. doi: 10.1002/1097-0142(19880101)61:1<195::aid-cncr2820610133>3.0.co;2-y. [DOI] [PubMed] [Google Scholar]
  29. Stearns M. E., Wang M., Tew K. D., Binder L. I. Estramustine binds a MAP-1-like protein to inhibit microtubule assembly in vitro and disrupt microtubule organization in DU 145 cells. J Cell Biol. 1988 Dec;107(6 Pt 2):2647–2656. doi: 10.1083/jcb.107.6.2647. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Waehre H., Wanderaas E. H., Paus E., Fosså S. D. Prediction of pelvic lymph node metastases by a prostate-specific antigen and prostatic acid phosphatase in clinical T3/T4M0 prostatic cancer. Eur Urol. 1992;22(1):33–38. doi: 10.1159/000474718. [DOI] [PubMed] [Google Scholar]
  31. Yagoda A., Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 1993 Feb 1;71(3 Suppl):1098–1109. doi: 10.1002/1097-0142(19930201)71:3+<1098::aid-cncr2820711432>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES